肾移植术后感染新型冠状病毒1例

The novel coronavirus is a newly discovered pathogen in late December 2019, and its source is currently unknown, which can lead to asymptomatic infection, new coronavirus pneumonia or serious complications, such as acute respiratory failure. Corona virus disease 2019 (COVID-19) is a new type of respiratory disease that is currently spreading all over the world and caused by this coronavirus. Its common symptoms are highly similar to those of other viruses, such as fever, cough and dyspnea. There is currently no vaccine or treatment for COVID-19. Everyone is susceptible to infection with this disease, and owing to the long-term use of immunosuppressants, the immunity of kidney transplant recipients is suppressed, and it is more likely to be infected with the disease. At present, its impact on kidney transplant recipients is unclear. This article reports the clinical features and therapeutic course of novel coronavirus infection in a patient after renal transplantation. A 37-year-old female patient who received a kidney transplant 6 months before was diagnosed with novel coronavirus pneumonia. The patient’s symptoms (such as fever, chills, dry cough, muscle aches), laboratory tests (such as decreased white blood cell count, elevated liver enzymes and D-dimer, positive viral nucleic acid test), and chest CT (multiple left lower lung plaque ground glass shadow) were similar to those of non-transplanted novel coronavirus pneumonia patients. In terms of treatment, because the immunity of kidney transplant recipients has been suppressed for a long time, it is a very common strategy to suspend the use of immunosuppressive agents. Therefore, the patient immediately discontinued the immunosuppressive agent after admission, so that she could restore immunity against infection in a short time. At the same time, the use of glucocorticoids was also very important. Its immunosuppressive and anti-inflammatory effects played a large role in the treatment process.In addition, prophylactic antibiotics was needed, and nephrotoxic drugs should be used with caution. Finally, following discounting the use of immunosuppressant and a low-dose glucocorticoid-based treatment regimen, COVID-19 in this renal transplant recipient was successfully cured. The cure of this case was of great significance, and this adjuvant nonspecific antiviral therapy could provide a template for the treatment of other such patients.     

肾移植术后感染新型冠状病毒1例

The novel coronavirus is a newly discovered pathogen in late December 2019, and its source is currently unknown, which can lead to asymptomatic infection, new coronavirus pneumonia or serious complications, such as acute respiratory failure. Corona virus disease 2019 (COVID-19) is a new type of respiratory disease that is currently spreading all over the world and caused by this coronavirus. Its common symptoms are highly similar to those of other viruses, such as fever, cough and dyspnea. There is currently no vaccine or treatment for COVID-19. Everyone is susceptible to infection with this disease, and owing to the long-term use of immunosuppressants, the immunity of kidney transplant recipients is suppressed, and it is more likely to be infected with the disease. At present, its impact on kidney transplant recipients is unclear. This article reports the clinical features and therapeutic course of novel coronavirus infection in a patient after renal transplantation. A 37-year-old female patient who received a kidney transplant 6 months before was diagnosed with novel coronavirus pneumonia. The patient’s symptoms (such as fever, chills, dry cough, muscle aches), laboratory tests (such as decreased white blood cell count, elevated liver enzymes and D-dimer, positive viral nucleic acid test), and chest CT (multiple left lower lung plaque ground glass shadow) were similar to those of non-transplanted novel coronavirus pneumonia patients. In terms of treatment, because the immunity of kidney transplant recipients has been suppressed for a long time, it is a very common strategy to suspend the use of immunosuppressive agents. Therefore, the patient immediately discontinued the immunosuppressive agent after admission, so that she could restore immunity against infection in a short time. At the same time, the use of glucocorticoids was also very important. Its immunosuppressive and anti-inflammatory effects played a large role in the treatment process.In addition, prophylactic antibiotics was needed, and nephrotoxic drugs should be used with caution. Finally, following discounting the use of immunosuppressant and a low-dose glucocorticoid-based treatment regimen, COVID-19 in this renal transplant recipient was successfully cured. The cure of this case was of great significance, and this adjuvant nonspecific antiviral therapy could provide a template for the treatment of other such patients.     

低氧状态及炎症反应是新型冠状病毒肺炎患者发生急性心肌损伤的危险因素

目的: 寻找新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)患者发生急性心肌损伤的危险因素。方法: 本研究为单中心COVID-19住院患者的回顾性队列研究,共纳入149例COVID-19确诊患者,依据2018年欧洲心脏病学会年会发布的第四版心肌梗死全球统一定义中关于心肌损伤的诊断标...     

6-OHDA所致帕金森病模型大鼠黑质FP1基因表达及启动子甲基化状态变化

目的研究6-羟基多巴胺(6-OHDA)所致帕金森病(PD)模型大鼠黑质膜铁转运蛋白1(FP1)基因表达及其启动子甲基化状态的变化。方法采用6-OHDA单侧损毁大鼠内侧前脑束(MFB),免疫组化方法观察脑黑质区酪氨酸羟化酶(TH)阳性神经元细胞存活情况,半定量逆转录聚合酶链反应(RT-PCR)技术检测黑质区FP1mRNA表达的变化,甲基化特异性PCR(MSP)检测FP1基因启动子区甲基化状态的变化。结果 6-OHDA单侧损毁大鼠MFB后,与未损毁侧及对照组相比,损毁侧中脑黑质区TH阳性细胞显著减少(t=20.619、18.404,P0.01),FP1表达下调(t=8.123、7.609,P0.01);与对照组相比,实验组注射侧FP1基因启动子区甲基化阳性率增高,差异有显著性(χ2=20.0,P0.01)。结论 6-OHDA所致PD大鼠模型中黑质FP1基因表达降低,该基因启动子区甲基化可能参与FP1的表达下调。     

桉叶油对体外培养人绒毛膜细胞生长及分泌功能的影响

目的：探讨桉叶油对体外培养人绒毛膜细胞生长及分泌功能的影响。方法胰酶消化法收集正常妊娠6~8周人绒毛膜细胞，分别用0.75、0.15、0.015、0.0015g·L-1的桉叶油作用12h、24h、48h，倒置显微镜观察细胞形态变化，活细胞计数测定细胞的生长曲线，MTT法检测桉叶油对细胞的抑制率，化学发光法检测细胞培养上清液中的雌激素、孕激素和绒毛膜促性腺激素的浓度。结果与对照组比较,质量浓度≥0.75g·L-1的桉叶油对绒毛膜细胞生长有明显的抑制作用（P<0.05）；质量浓度≤0.15g/L的桉叶油对绒毛膜细胞生长的抑制率与对照组比较无明显差异（P＞0.05）。桉叶油作用绒毛膜细胞24h 时，0.75g/L桉叶油组细胞上清液中雌二醇、孕激素浓度均较对照组显著降低（P<0.05），其余各组细胞上清液中雌二醇、孕激素浓度均与对照组比较无差异。桉叶油作用绒毛膜细胞24h时，桉叶油各组细胞上清液中绒毛膜促性腺激素浓度较对照组显著增高（P<0.05）。结论质量浓度≥0.75g/L桉叶油对人绒毛膜细胞生长有抑制作用，质量浓度≤0.15g/L桉叶油对人绒毛膜细胞生长无抑制作用。桉叶油对体外培养的绒毛膜细胞分泌雌二醇、孕激素无明显影响，但可刺激绒毛膜细胞分泌HCG。     

以腹泻为首发症状的新型冠状病毒肺炎患者临床特征和病情严重程度及其影响因素研究

背景　部分新型冠状病毒肺炎（COVID-19）患者存在胃肠道症状,但目前关于以腹泻为首发症状的COVID-19患者临床特征及预后的研究报道较少见。目的　分析以腹泻为首发症状的COVID-19患者的临床特征、病情严重程度及其影响因素。方法　北京大学援鄂医疗队于2020-01-28至2020-02-28共接管华中科技大学同济医学院附属同济医院中法新城院区隔离病房中鼻咽拭子样本2019新型冠状病毒（SARS-CoV-2）RNA检测结果为阳性的COVID-19患者207例,选取其中由北京大学第三医院医疗分队接管的以腹泻为首发症状者17例作为观察组,未以腹泻为首发症状者34例作为对照组。比较两组患者一般资料、临床症状、血常规检查结果、肝功能指标、血脂指标、肌酐、凝血功能指标、炎性指标、降钙素原、心肌损伤指标、胸部CT检查结果、临床分型、最高体温、治疗情况、并发症发生情况、生存情况、发病至治疗时间、住院时间;COVID-19患者病情严重程度的影响因素分析采用单因素及多因素Logistic分析。结果　观察组患者咳痰发生率、D-二聚体、降钙素原异常率、临床分型为重型及危重型者所占比例低于对照组,乏力发生率、白蛋白高于对照组,凝血酶原时间、住院时间短于对照组（P<0.05）。多因素Logistic回归分析结果显示,白蛋白〔OR=0.739,95%CI（0.569,0.960）〕是COVID-19患者病情严重程度的保护因素,而降钙素原〔OR=7.349,95%CI（1.213,44.513）〕是危险因素（P<0.05）。结论　以腹泻为首发症状的COVID-19患者呼吸道症状及病情严重程度较轻、乏力发生率较高、临床分型以普通型为主、同等治疗情况下住院时间较短;白蛋白是COVID-19患者病情严重程度的保护因素,而降钙素原是危险因素,临床应注意加强对白蛋白及降钙素原的监测。